Showing: 1 - 10 of 14 RESULTS
Analyst Estimate Briefing Numinus Wellness Inc Psychedelics

Numinus Wellness: Eight Capital Initiates With $1.10 Price Target

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The fourth company initiated on this note is Numinus Wellness Inc. (TSXV: NUMI), with a C$1.10 12-month price target and buy rating while referring to the firm as “a diversified operator.” …

Analyst Estimate Briefing Bright Minds Biosciences News Psychedelics

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …

Analyst Estimate Briefing Mind Medicine Psychedelics

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. They say that after a large influx of capital and “a growing body of clinical trial data on the use of psychedelics and related substances demonstrating a remarkable degree of …

Analyst Estimate Briefing Field Trip Health Psychedelics

Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The third company on this list is Field Trip Health (CSE: FTRP) with a C$10.20 12-month price target and buy rating. Field Trip Health currently has 3 analysts covering the …

Analyst Estimate Briefing Bright Minds Biosciences Compass Pathways Cybin Inc Field Trip Health Mind Medicine Mindset Pharma Numinus Wellness Inc Psychedelics Small Pharma Inc

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing unmet need in mental health” and that this need has only been growing steadily but has been exacerbated by the COVID-19 pandemic. In this 27 page primer Sepehr Manochehry, their analyst, highlights COMPASS Pathways (NASDAQ: …

Analyst Estimate Briefing Psyched Wellness Psychedelics

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could mature into leaders within their respective fields, some as soon as this year.” To start off this note, Tania Gonsalves says that in the past year, 20+ psychedelic companies have gone public, and 14 existing companies have now pivoted to …